vs
Side-by-side financial comparison of Outdoor Holding Co (POWW) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $13.4M, roughly 1.4× Outdoor Holding Co). SCYNEXIS INC runs the higher net margin — 65.7% vs 16.7%, a 49.1% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs -54.1%).
Vista Outdoor Inc. was an American designer, manufacturer, and marketer that operated in two segments: shooting sports and outdoor products. It was a "house of brands" with more than 40 labels and subsidiaries.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
POWW vs SCYX — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.4M | $18.6M |
| Net Profit | $2.2M | $12.3M |
| Gross Margin | 87.1% | — |
| Operating Margin | 14.7% | 56.3% |
| Net Margin | 16.7% | 65.7% |
| Revenue YoY | -54.1% | 1808.5% |
| Net Profit YoY | 108.5% | 376.5% |
| EPS (diluted) | $0.01 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.4M | $18.6M | ||
| Q3 25 | $12.0M | $334.0K | ||
| Q2 25 | $11.9M | $1.4M | ||
| Q1 25 | $12.6M | $257.0K | ||
| Q4 24 | $12.5M | $977.0K | ||
| Q3 24 | $12.0M | $660.0K | ||
| Q2 24 | $12.3M | $736.0K | ||
| Q1 24 | $-50.7M | $1.4M |
| Q4 25 | $2.2M | $12.3M | ||
| Q3 25 | $1.4M | $-8.6M | ||
| Q2 25 | $-6.5M | $-6.9M | ||
| Q1 25 | $-77.5M | $-5.4M | ||
| Q4 24 | $-26.1M | — | ||
| Q3 24 | $-12.4M | $-2.8M | ||
| Q2 24 | $-14.8M | $-14.5M | ||
| Q1 24 | $-5.2M | $411.0K |
| Q4 25 | 87.1% | — | ||
| Q3 25 | 87.1% | — | ||
| Q2 25 | 87.2% | — | ||
| Q1 25 | 87.5% | — | ||
| Q4 24 | 87.4% | — | ||
| Q3 24 | 86.9% | — | ||
| Q2 24 | 85.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | 14.7% | 56.3% | ||
| Q3 25 | 5.9% | -2516.5% | ||
| Q2 25 | -50.7% | -701.0% | ||
| Q1 25 | -213.6% | -3350.2% | ||
| Q4 24 | -163.8% | — | ||
| Q3 24 | -50.3% | -1563.6% | ||
| Q2 24 | -50.8% | -1255.0% | ||
| Q1 24 | — | -692.5% |
| Q4 25 | 16.7% | 65.7% | ||
| Q3 25 | 11.7% | -2572.2% | ||
| Q2 25 | -54.5% | -504.8% | ||
| Q1 25 | -614.5% | -2097.7% | ||
| Q4 24 | -208.7% | — | ||
| Q3 24 | -103.7% | -425.5% | ||
| Q2 24 | -120.2% | -1964.4% | ||
| Q1 24 | 10.3% | 29.9% |
| Q4 25 | $0.01 | $0.25 | ||
| Q3 25 | $0.01 | $-0.17 | ||
| Q2 25 | $-0.06 | $-0.14 | ||
| Q1 25 | $-0.67 | $-0.11 | ||
| Q4 24 | $-0.23 | — | ||
| Q3 24 | $-0.11 | $-0.06 | ||
| Q2 24 | $-0.13 | $-0.30 | ||
| Q1 24 | $-0.05 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $69.9M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $237.3M | $49.4M |
| Total Assets | $271.7M | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $69.9M | $40.0M | ||
| Q3 25 | $65.7M | $37.9M | ||
| Q2 25 | $63.4M | $44.8M | ||
| Q1 25 | $30.2M | $40.6M | ||
| Q4 24 | $31.9M | $59.3M | ||
| Q3 24 | $33.5M | $68.8M | ||
| Q2 24 | $50.8M | $73.0M | ||
| Q1 24 | $55.6M | $80.2M |
| Q4 25 | $237.3M | $49.4M | ||
| Q3 25 | $235.4M | $36.4M | ||
| Q2 25 | $222.5M | $44.5M | ||
| Q1 25 | $222.0M | $50.5M | ||
| Q4 24 | $299.6M | $55.1M | ||
| Q3 24 | $325.6M | $58.5M | ||
| Q2 24 | $342.5M | $60.4M | ||
| Q1 24 | $358.0M | $74.1M |
| Q4 25 | $271.7M | $59.0M | ||
| Q3 25 | $270.3M | $51.1M | ||
| Q2 25 | $269.5M | $60.7M | ||
| Q1 25 | $297.3M | $67.9M | ||
| Q4 24 | $355.4M | $90.6M | ||
| Q3 24 | $368.9M | $99.0M | ||
| Q2 24 | $398.6M | $107.8M | ||
| Q1 24 | $403.0M | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.7M | $18.4M |
| Free Cash FlowOCF − Capex | $5.0M | — |
| FCF MarginFCF / Revenue | 37.6% | — |
| Capex IntensityCapex / Revenue | 4.8% | — |
| Cash ConversionOCF / Net Profit | 2.55× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $-2.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.7M | $18.4M | ||
| Q3 25 | $3.2M | $-8.7M | ||
| Q2 25 | $-6.7M | $-7.5M | ||
| Q1 25 | $-1.5M | $-7.5M | ||
| Q4 24 | $1.3M | $-24.0M | ||
| Q3 24 | $-9.3M | $765.0K | ||
| Q2 24 | $-547.5K | $-10.9M | ||
| Q1 24 | $4.3M | $-4.0M |
| Q4 25 | $5.0M | — | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $-7.6M | — | ||
| Q1 25 | $-2.3M | — | ||
| Q4 24 | $720.3K | — | ||
| Q3 24 | $-10.6M | — | ||
| Q2 24 | $-1.3M | — | ||
| Q1 24 | $1.4M | — |
| Q4 25 | 37.6% | — | ||
| Q3 25 | 21.0% | — | ||
| Q2 25 | -63.8% | — | ||
| Q1 25 | -18.6% | — | ||
| Q4 24 | 5.8% | — | ||
| Q3 24 | -88.3% | — | ||
| Q2 24 | -11.0% | — | ||
| Q1 24 | -2.8% | — |
| Q4 25 | 4.8% | — | ||
| Q3 25 | 5.8% | — | ||
| Q2 25 | 7.5% | — | ||
| Q1 25 | 6.5% | — | ||
| Q4 24 | 4.4% | — | ||
| Q3 24 | 10.4% | — | ||
| Q2 24 | 6.5% | — | ||
| Q1 24 | -5.7% | — |
| Q4 25 | 2.55× | 1.50× | ||
| Q3 25 | 2.29× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
POWW
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
